Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.
Abstract
HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequences may ultimately impact on the adherence to treatment of patients, eventually leading to treatment failure. Despite considerable advances in recent times, the pathogenesis of HALS remains elusive. Factors involved belong to three categories: those intrinsic to the host, some of them modifiable and some not, those associated with antiretroviral therapy, that are sometimes modifiable as well, and finally those related to HIV-1 infection and its consequences, most often not modifiable. The most commonly used strategies for HALS reversion have included host-dependent factors such as lifestyle and dietary modifications and antiretroviral-dependent factors such as switching or avoiding the use of drugs more prone to promote HALS. Lifestyle modifications and switching thymidine analogues have been associated with moderate success. Pharmacological interventions have included the use of insulin-sensitising agents and hormone therapy with disappointing results, whereas treatment with pravastatin or pioglitazone, and uridine supplementation seem to be associated with fat gain in preliminary studies. The only interventions with almost immediate results that may render a patient's appearance similar to his past one have included filling techniques for facial lipoatrophy and ultrasound-assisted liposuction for cervical fat pad hypertrophy. Among the filling options, semipermanent reabsorbable materials and autologous fat transfer have been associated with acceptable outcomes. As of now, the best hope should rely on the use of drugs friendly for fat, on defining the appropriate timing for starting antiretroviral and on continuing the research effort to understand the basic mechanisms underlying HALS pathogenesis. Only through this effort can the best chances for preventing or reverting established HALS be recognised.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | liposuction
|
지방흡입 | dict | 1 | |
| 해부 | adipose
|
scispacy | 1 | ||
| 해부 | fat
|
scispacy | 1 | ||
| 해부 | cervical fat pad
|
scispacy | 1 | ||
| 합병증 | infection
|
감염 | dict | 1 | |
| 약물 | thymidine
|
C0040077
thymidine
|
scispacy | 1 | |
| 약물 | pravastatin
|
C0085542
pravastatin
|
scispacy | 1 | |
| 약물 | pioglitazone
|
C0071097
pioglitazone
|
scispacy | 1 | |
| 약물 | uridine
|
C0041984
uridine
|
scispacy | 1 | |
| 질환 | HIV-1-associated adipose redistribution
|
scispacy | 1 | ||
| 질환 | therapy-associated lipodystrophy syndrome
|
scispacy | 1 | ||
| 질환 | HIV-1 infection
|
scispacy | 1 | ||
| 질환 | fat gain
|
scispacy | 1 | ||
| 질환 | facial lipoatrophy
|
C5194461
Facial lipoatrophy
|
scispacy | 1 | |
| 질환 | hypertrophy
|
C0020564
Hypertrophy
|
scispacy | 1 | |
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 |
MeSH Terms
Adipose Tissue; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Face; HIV-Associated Lipodystrophy Syndrome; Humans; Life Style; Lipectomy; Patient Compliance; Quality of Life; Surgery, Plastic
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Penetrating globe injury following periocular hyaluronic acid filler injection: A case report.
- Implications of Dermatologic Disorders in Facial Cosmetic Surgery: A Systematic Review.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.
- Otoplasty for prominent ear: A systematic review of surgical techniques.
- 3D printing-guided chest wall reconstruction - a case report and literature review.